BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8845570)

  • 1. Immunophenotype and DNA cell content in multiple myeloma.
    San Miguel JF; Garcia-Sanz R; Gonzalez M; Orfao A
    Baillieres Clin Haematol; 1995 Dec; 8(4):735-59. PubMed ID: 8845570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
    Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA cell content studies in multiple myeloma.
    San Miguel JF; García-Sanz R; González M; Orfão A
    Leuk Lymphoma; 1996 Sep; 23(1-2):33-41. PubMed ID: 9021683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.
    García-Sanz R; Orfão A; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Br J Haematol; 1995 May; 90(1):106-12. PubMed ID: 7786771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
    Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
    Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface markers in multiple myeloma.
    Ruiz-Argüelles GJ; San Miguel JF
    Mayo Clin Proc; 1994 Jul; 69(7):684-90. PubMed ID: 8015335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
    McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
    Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics.
    Omedè P; Boccadoro M; Fusaro A; Gallone G; Pileri A
    Br J Haematol; 1993 Nov; 85(3):504-13. PubMed ID: 8136273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
    Mateo G; Castellanos M; Rasillo A; Gutiérrez NC; Montalbán MA; Martín ML; Hernández JM; López-Berges MC; Montejano L; Bladé J; Mateos MV; Sureda A; de la Rubia J; Díaz-Mediavilla J; Pandiella A; Lahuerta JJ; Orfao A; San Miguel JF
    Clin Cancer Res; 2005 May; 11(10):3661-7. PubMed ID: 15897562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique.
    Orfäo A; García-Sanz R; López-Berges MC; Belén Vidriales M; González M; Caballero MD; San Miguel JF
    Cytometry; 1994 Dec; 17(4):332-9. PubMed ID: 7533074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
    Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
    Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
    López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
    Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
    García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
    Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients--diagnostic and clinical implications.
    Luque R; Brieva JA; Moreno A; Manzanal A; Escribano L; Villarrubia J; Velasco JL; López-Jiménez J; Cerveró C; Otero MJ; Martínez J; Bellas C; Roldán E
    Clin Exp Immunol; 1998 Jun; 112(3):410-8. PubMed ID: 9649209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
    Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
    Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
    San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
    Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
    Pilarski LM; Giannakopoulos NV; Szczepek AJ; Masellis AM; Mant MJ; Belch AR
    Clin Cancer Res; 2000 Feb; 6(2):585-96. PubMed ID: 10690543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
    Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
    Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.